Our model

Nuformix early-stage pipeline of preclinical and Phase 1-ready assets has potential for significant value and early licensing opportunities


Our business model is to take our assets to key value inflection points before partnering or licensing. Development is conducted virtually, with research and development activities out-sourced to a network of external contractors.